ISSN:0902-4441    

DOI:10.1111/j.1600-0609.1987.tb01414.x

出版商:Blackwell Publishing Ltd    

年代:1987

数据来源: WILEY

ISSN:0902-4441    

DOI:10.1111/j.1600-0609.1987.tb01415.x

出版商:Blackwell Publishing Ltd    

年代:1987

数据来源: WILEY

摘要:

15 patients with acute myeloid leukaemia (AML) were treated with low‐dose cytosine arabinoside (LD ARA‐C). 2 patients had complete remissions, which lasted for 8 and 3 months, and 5 patients had a partial remission. 46% of the patients thus responded to LD ARA‐C. This included 1 responding patient who had not previously responded to therapy with 6‐mercaptopurine, thioguanine, or vinblastine. The 2 patients with complete remission did not show LD ARA‐C‐induced hypoplasia of bone marrow, although 1 had hypoplastic AML before therapy. Leukaemic cells from 1 patient showed in vivo maturation from M1 to M3 after LD ARA‐C treatment. The present results, together with the published data, indicate that:a.LD ARA‐C treatment, although it may have some toxic effects, is an effective treatment for some patients with AML, especially those with hypoplastic AML;b.Response to LD ARA‐C can be obtained after one or several courses of treatment;c.LD ARA‐C‐induced remissions are sometimes obtained even in patients who fail in more conventional treatments;d.LD ARA‐C‐induced remissions can be achieved without bone marrow hypoplasia, and induction of hypoplasia by itself does not always result in complete remission;e.LD ARA‐C can induce in vivo maturation of leukaemic cells. It is suggested that induction of remission in AML patients by LD ARA‐C may result from either differentiation of leukaemic blast cells, cytotoxicity to leukaemic blasts, or bo

ISSN:0902-4441    

DOI:10.1111/j.1600-0609.1987.tb01416.x

出版商:Blackwell Publishing Ltd    

年代:1987

数据来源: WILEY

摘要:

Per cent stimulation of GR activity by FAD in vitro and PNP oxidase activity were measured in G6PD deficiency, heterozygous β‐thalassaemia and controls. It is confirmed that, in contrast to the high stimulation of GR by FAD commonly found in thalassaemia indicating red‐cell deficiency of FAD, and shown here to be greater in the Italian subjects, GR is usually saturated with FAD in G6PD deficiency, leading to high in vitro activity. Unexpectedly, on the other hand, low FMN‐dependent PNP oxidase activity due to red‐cell deficiency of FMN, confirmed by response to oral riboflavin, was found in the majority of subjects with G6PD deficiency, similar to that found in heterozygous β‐thalassaemia. Whereas this is explained in thalassaemia by an inherited slow red‐cell metabolism of riboflavin to FMN, it is suggested that in G6PD deficiency an increased rate of red‐cell metabolism of FMN to FAD leads to the low FMN and high FAD. When G6PD deficiency occurs with heterozygous β‐thalassaemia, GR is usually saturated with FAD as in G6PD deficiency alone, unless there is an inherited, very slow red‐cell metabolism of riboflavin to FMN. The part played by GR in haemolytic crises in G6PD def

ISSN:0902-4441    

DOI:10.1111/j.1600-0609.1987.tb01417.x

出版商:Blackwell Publishing Ltd    

年代:1987

数据来源: WILEY

摘要:

A rosette assay was developed for the detection of haem receptor‐bearing cells. Indicator particles were prepared by covalent binding of haem to acrylic microbeads. The new method was tested on K562 human erythroleukaemia cells, known to take up haem. In tests on several batches, 80–90% of the K562 cells were rosetted with haemmicrobeads whereas mature erythrocytes were haem receptor‐negative. Rosette formation was inhibited in a dose‐dependent manner by micromolar concentrations of free haemin but not by albumin or transferrin. Uncoated microbeads or albumin‐coated microbeads did not attach to K562 cells but transferrin‐coated microbeads rosetted 50–70% of them. Diferric transferrin inhibited these rosettes, but haemin

ISSN:0902-4441    

DOI:10.1111/j.1600-0609.1987.tb01418.x

出版商:Blackwell Publishing Ltd    

年代:1987

数据来源: WILEY

摘要:

A monoclonal antibody to IL2 receptor Tac/CD25 antigen was included in the phenotyping panel of 92 leukemic proliferations. Spontaneous expression of this molecule was observed in one disorder of T‐phenotype only, but in 75% of B‐chronic lymphocytic leukemia (CLL) and on cells from B‐cell leukemic lymphomas. These findings provide further evidence for a non‐T‐cell restriction of IL2 receptor and raise the question of multiple gene derepression in hematologic disorders of

ISSN:0902-4441    

DOI:10.1111/j.1600-0609.1987.tb01419.x

出版商:Blackwell Publishing Ltd    

年代:1987

数据来源: WILEY

摘要:

The number of specific (3H)ouabain binding sites and dissociation constants (Kd) were determined by Scatchard analysis of values for leucocytes from patients with B‐cell chronic lymphocytic leukaemia (CLL), chronic myeloid leukaemia (CML), acute blastic leukaemia (AL) and healthy subjects. CLL lymphocytes and normal B‐cells bound significantly less (3H)ouabain than did normal T‐lymphocytes. CML granulocytes showed the same binding characteristics as normal granulocytes, while blast cells from AL patients bound significantly more (3H)ouabain than did normal granulocytes or B‐cells. The increased binding capacity in blast cells might, at least partly, reflect their larger cell size. A decrease in Kdvalues was only found in CLL lymphocytes, as compared with normal B‐cells. Intralymphocytic sodium content in CLL lymphocytes was significantly increased, as compared with that in T‐cell‐enriched normal lymphocytes. (3H)ouabain binding did not show any relationship to different prognostic variables in CLL. The present data mainly argue against altered Na+/K+‐ATPase enzyme activity as an indicato

ISSN:0902-4441    

DOI:10.1111/j.1600-0609.1987.tb01420.x

出版商:Blackwell Publishing Ltd    

年代:1987

数据来源: WILEY

摘要:

Plasma fibronectin concentrations were studied in 10 patients with multiple myeloma. After plasma exchange for 3 d (2.5‐3 1 plasma daily) the plasma fibronectin decreased to about 50% of the initial level. Resynthesis of fibronectin seemed to increase during 3 d of plasmapheresis, and was sufficient to normalize plasma fibronectin concentration. The plasma fibronectin concentration reached the initial level within 2 d after interrupting plasmapheresis in spite of concurrent cytotoxic treatment. The patients studied showed no signs of infectio

ISSN:0902-4441    

DOI:10.1111/j.1600-0609.1987.tb01421.x

出版商:Blackwell Publishing Ltd    

年代:1987

数据来源: WILEY

摘要:

Prognosis in multiple myeloma (MM) is related to the establishment of an immunologically and kinetically characteristic plateau phase. Patients who present with this state may not benefit from immediate chemotherapy. We assessed 20 patients with MM who were staged according to the Salmon and Durie classification at diagnosis and monitored throughout the course of their disease. Patients with a lambda paraprotein and a kappa/lambda lymphocyte ratio in the blood greater than 4.0 were considered to demonstrate light chain isotype suppression (LCIS). Similarly, patients with a kappa paraprotein and a kappa/lambda ratio of less than 0.55 were also considered to have LCIS (1). 14 patients had LCIS; of these, 6 were classified as stage IA, 2 as stage IB, 3 as stage IIA, and 3 as stage IIIA. 6 patients did not have LCIS; 3 were classified as stage IIA, 1 as stage IIIA and 2 as stage IIIB. 10 patients with LCIS were assessed for treatment benefit following administration of melphalan and prednisone, as defined by a fall in the serum paraprotein level of>50% over 6 months. In 8 patients the serum paraprotein levels did not fall, and the patients remained in good health without clinical deterioration. Thus LCIS at presentation may indicate patients in whom treatment can be safely deferred or in whom aggressive therapy is not indicated.

ISSN:0902-4441    

DOI:10.1111/j.1600-0609.1987.tb01422.x

出版商:Blackwell Publishing Ltd    

年代:1987

数据来源: WILEY

摘要:

In a randomised multicentre trial a combination of methylprednisolone, vincristine, CCNU, cyclophosphamide and melphalan (MOCCA) was compared with intermittent melphalan and prednisone (MP) as primary treatment in multiple myeloma. In the MP arm the refractory or relapsed patients were treated with regimen MOCCA. The MOCCA arm produced a response rate of 75% among 64 patients and the MP arm a respone rate of 54% among 66 patients. The median surival was 41 months in the MOCCA arm and 45 months in the patients primarily randomised to the MP arm. The initial response to MOCCA improved the survival, while this effect was not statistically significant in the MP arm. The results show that the median surivival does not increase if aggressive chemotherapy is employed as the first line treatment in multiple myeloma.

ISSN:0902-4441    

DOI:10.1111/j.1600-0609.1987.tb01423.x

出版商:Blackwell Publishing Ltd    

年代:1987

数据来源: WILEY